Skip to content

SAFE: Sequre for Adenomyosis and Fibroid Embolisation

SAFE: Sequre for Adenomyosis and Fibroid Embolisation - SAFE

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON52676
Enrollment
30
Registered
2021-12-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

uterus fibroids and adenomyosis

Interventions

Embolization of myomas and/or adenomyosis (UAE) with the microcatheter 2.8F, performed by experienced intervention radiologists. Results are compared with retrospective status studies.

Sponsors

Sint Elisabeth Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - premenopausal woman, age > 30yrs and

Exclusion criteria

Exclusion criteria: - fibroid >= 5 cm - pregnancy - seeking future pregnancy - presence or suspicion of any gynaecologic malignancy - presence or suspicion of any pelvic inflammatory disease - pelvic congestion syndrome - already infarcted / calcified leiomyomata - bleeding disorder - renal function disorder

Design outcomes

Primary

MeasureTime frame
QOL scores and MRI (the difference in volume) are the two main study endpoints.

Secondary

MeasureTime frame
The secondary study endpoints are: - Number vials / ml particles used (+ size) - Number of protection coils used to avoid advert side branch non target embolization - Complications - Imaging post-procedure at 3 month follow up MRI: % necrosis (infarction 100% - 95- 100% or

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)